Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA
For a menopausal woman already navigating the muscle loss that estrogen withdrawal and the aging process impose, that trade-off carries significant long-term consequences
Were Here To Help You Find Your Way Would you like more information about mental health or drug addiction
Conta il principio attivo, il dosaggio, lindicazione e la risposta individuale
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
Insurance coverage, medication affordability, and access issues can significantly influence whether treatment continues